Therapeutic Targeting of the IGF Axis

Acromegaly

(2019) Annamaria Colao et al.   Nature Reviews Disease Primers

Bad to the Bone: The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis

(2019) Guillaume Rieunier et al.   CLINICAL CANCER RESEARCH

VEGF in Signaling and Disease: Beyond Discovery and Development

(2019) Rajendra S. Apte et al.   CELL

Acromegaly associated with GIST, non-small cell lung carcinoma, clear cell renal carcinoma, multiple myeloma, medulla oblongata tumour, adrenal adenoma, and follicular thyroid nodules

(2019) Aleksandra Jawiarczyk-Przybyłowska et al.   Endokrynologia Polska

MANAGEMENT OF ENDOCRINE DISEASE: Bone disorders associated with acromegaly: mechanisms and treatment

(2019) Gherardo Mazziotti et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Targeting IGF-1/2 with xentuzumab (Xe) plus enzalutamide (En) in metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel chemotherapy (DCt) and abiraterone (Abi): Randomized phase II trial results.

(2019) Syed A. Hussain et al.   JOURNAL OF CLINICAL ONCOLOGY

The Influence of Curcumin on the Downregulation of MYC, Insulin and IGF-1 Receptors: A possible Mechanism Underlying the Anti-Growth and Anti-Migration in Chemoresistant Colorectal Cancer Cells

(2019) Seyed Ahmad Hosseini et al.   Medicina-Lithuania

Acromegaly and Heart Failure

(2019) Annamaria Colao et al.   Heart Failure Clinics

Nuclear IGF-1R interacts with regulatory regions of chromatin to promote RNA polymerase II recruitment and gene expression associated with advanced tumor stage

(2018) Tamara Aleksic et al.   CANCER RESEARCH

Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer

(2018) Amit Oza et al.   GYNECOLOGIC ONCOLOGY

Etanercept for the treatment of rheumatoid arthritis

(2018) Sizheng Zhao et al.   Immunotherapy

A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC)

(2018) Pedro Barata et al.   INVESTIGATIONAL NEW DRUGS

Insulin/IGF-driven cancer cell-stroma crosstalk as a novel therapeutic target in pancreatic cancer

(2018) Ayse Ceren Mutgan et al.   Molecular Cancer

β-catenin/TCF activity regulates IGF-1R tyrosine kinase inhibitor sensitivity in colon cancer

(2018) Hani Lee et al.   ONCOGENE

How ligand binds to the type 1 insulin-like growth factor receptor

(2018) Yibin Xu et al.   Nature Communications

Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice

(2018) Kai Mao et al.   Nature Communications

Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy

(2018) Terry J Smith et al.   ENDOCRINE REVIEWS

Hepatocyte growth factor‑induced mesenchymal‑epithelial transition factor activation leads to insulin‑like growth factor 1 receptor inhibitor unresponsiveness in gastric cancer cells

(2018) Rujiao Liu et al.   Oncology Letters

Predominance of triple wild-type and IGF2R mutations in mucosal melanomas

(2018) Yuuki Iida et al.   BMC CANCER

Enhanced anti-metastatic bioactivity of an IGF-TRAP re-engineered to improve physicochemical properties

(2018) George Vaniotis et al.   Scientific Reports

The insulin like growth factor and binding protein family: Novel therapeutic targets in obesity & diabetes

(2018) Natalie J. Haywood et al.   Molecular Metabolism

IGF-binding proteins

(2017) L A Bach   JOURNAL OF MOLECULAR ENDOCRINOLOGY

The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy

(2017) Michael P. Sanderson et al.   MOLECULAR CANCER THERAPEUTICS

Teprotumumab for Thyroid-Associated Ophthalmopathy

(2017) Terry J. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms

(2017) C Unger et al.   ONCOGENE

Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies

(2017) Aaron Simpson et al.   Targeted Oncology

Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma

(2017) Sam Behjati et al.   Nature Communications

Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response

(2017) Robert Aiken et al.   Oncotarget

Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy

(2017) Xiao Qu et al.   Oncotarget

Overcoming Linsitinib intrinsic resistance through inhibition of nuclear factor-κ B signaling in esophageal squamous cell carcinoma

(2017) Junzhou Wu et al.   Cancer Medicine

Phase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or without letrozole in aromatase inhibitor-resistant breast cancer.

(2017) P. Haluska et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer

(2016) Michael Bergqvist et al.   ACTA ONCOLOGICA

The role of insulin/IGF-1 signaling in the longevity of model invertebrates, C. elegans and D. melanogaster

(2016) Ozlem Altintas et al.   BMB Reports

A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk

(2016) Ruth C. Travis et al.   CANCER RESEARCH

A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors

(2016) Emiliano Calvo et al.   CLINICAL CANCER RESEARCH

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors

(2016) V. M. Macaulay et al.   CLINICAL CANCER RESEARCH

Ewing sarcoma: The clinical relevance of the insulin-like growth factor 1 and the poly-ADP-ribose-polymerase pathway

(2016) Annemiek M. van Maldegem et al.   EUROPEAN JOURNAL OF CANCER

MANAGEMENT OF ENDOCRINE DISEASE: Acromegaly and cancer: an old debate revisited

(2016) Cesar Luiz Boguszewski et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Association of insulin-like growth factor (IGF)-1 gene polymorphisms with plasma levels of IGF-1 and acne severity

(2016) Shekh Mohammad Amanur Rahaman et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Landscape of somatic mutations in 560 breast cancer whole-genome sequences

(2016) Serena Nik-Zainal et al.   NATURE

Combine and conquer: challenges for targeted therapy combinations in early phase trials

(2016) Juanita S. Lopez et al.   Nature Reviews Clinical Oncology

A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma

(2016) Peter M. Anderson et al.   PEDIATRIC BLOOD & CANCER

Functional evolution of IGF2:IGF2R domain 11 binding generates novel structural interactions and a specific IGF2 antagonist

(2016) Susana Frago et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas

(2016) D. F. Quail et al.   SCIENCE

Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFR

(2016) Tamara Aleksic et al.   Frontiers in Oncology

Impact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer

(2016) Chao H. Huang et al.   Frontiers in Oncology

Interventions to Slow Aging in Humans: Are We Ready?

(2015) Valter D. Longo et al.   AGING CELL

Evaluation of insulin like growth factor-1 (IGF-1) level and its impact on muscle and bone mineral density in frail elderly male

(2015) Magda I. Mohamad et al.   ARCHIVES OF GERONTOLOGY AND GERIATRICS

A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer

(2015) Samuel J. Vidal et al.   CANCER CELL

Gene therapy for cancer: regulatory considerations for approval

(2015) S R Husain et al.   CANCER GENE THERAPY

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer

(2015) A. DeMichele et al.   CLINICAL CANCER RESEARCH

LESSONS FROM 50 YEARS OF STUDY OF LARON SYNDROME

(2015) Zvi Laron   Endocrine Practice

Graves’ Disease Mechanisms: The Role of Stimulating, Blocking, and Cleavage Region TSH Receptor Antibodies

(2015) S. Morshed et al.   HORMONE AND METABOLIC RESEARCH

SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer

(2015) Evan Y. Yu et al.   JOURNAL OF CLINICAL ONCOLOGY

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory,KRASWild-Type, Metastatic Colorectal Cancer

(2015) Francesco Sclafani et al.   JNCI-Journal of the National Cancer Institute

Insulin-Like Growth Factor-1 Related to Disability Among Older Adults

(2015) Takehiko Doi et al.   JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES

Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study

(2015) Martin Fassnacht et al.   LANCET ONCOLOGY

Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor

(2015) A. Forest et al.   MOLECULAR CANCER RESEARCH

The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis

(2015) N. Wang et al.   MOLECULAR CANCER THERAPEUTICS

A Novel Neutralizing Antibody Targeting Pregnancy-Associated Plasma Protein-A Inhibits Ovarian Cancer Growth and Ascites Accumulation in Patient Mouse Tumorgrafts

(2015) M. A. Becker et al.   MOLECULAR CANCER THERAPEUTICS

Minireview: Were the IGF Signaling Inhibitors All Bad?

(2015) Heather Beckwith et al.   MOLECULAR ENDOCRINOLOGY

Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds

(2015) A.R.M. Ruhul Amin et al.   SEMINARS IN CANCER BIOLOGY

STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibody

(2015) Ji-Sun Lee et al.   Nature Communications

IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide

(2015) Roger Ramcharan et al.   Oncotarget

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory,KRASWild-Type, Metastatic Colorectal Cancer

(2015) Francesco Sclafani et al.   JNCI-Journal of the National Cancer Institute

IGF-1 Receptor and Adhesion Signaling: An Important Axis in Determining Cancer Cell Phenotype and Therapy Resistance

(2015) Orla T. Cox et al.   Frontiers in Endocrinology

Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via Insulin-like growth factor-1 receptor-independent mechanism

(2015) Ahmed Waraky et al.   Oncotarget

Low insulin-like growth factor-1 level predicts survival in humans with exceptional longevity

(2014) Sofiya Milman et al.   AGING CELL

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours

(2014) I Brana et al.   BRITISH JOURNAL OF CANCER

A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance

(2014) Alberto S. Pappo et al.   CANCER

Targeting cancer stem cells by curcumin and clinical applications

(2014) Yanyan Li et al.   CANCER LETTERS

Low Protein Intake Is Associated with a Major Reduction in IGF-1, Cancer, and Overall Mortality in the 65 and Younger but Not Older Population

(2014) Morgan E. Levine et al.   Cell Metabolism

Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors

(2014) P. Haluska et al.   CLINICAL CANCER RESEARCH

Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer

(2014) J. S. de Bono et al.   CLINICAL CANCER RESEARCH

Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors

(2014) R. L. Jones et al.   CLINICAL CANCER RESEARCH

Crosstalk between IGF-1R and other Tumor Promoting Pathways

(2014) Changyu Liu et al.   CURRENT PHARMACEUTICAL DESIGN

Quantification of Binding of IGF-1 to BI 836845, a Candidate Therapeutic Antibody Against IGF-1 and IGF-2, and Effects of This Antibody on IGF-1:IGFBP-3 Complexes In Vitro and in Male C57BL/6 Mice

(2014) Matei Mireuta et al.   ENDOCRINOLOGY

Chemopreventive effects of curcumin on chemically induced mouse skin carcinogenesis in BK5.insulin-like growth factor-1 transgenic mice

(2014) Hyoseon Kim et al.   IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL

A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors

(2014) Margaret von Mehren et al.   INVESTIGATIONAL NEW DRUGS

Nuclear FAM21 participates in NF- B-dependent gene regulation in pancreatic cancer cells

(2014) Z.-H. Deng et al.   JOURNAL OF CELL SCIENCE

Teprotumumab, an IGF-1R Blocking Monoclonal Antibody Inhibits TSH and IGF-1 Action in Fibrocytes

(2014) Hong Chen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Human GH Receptor-IGF-1 Receptor Interaction: Implications for GH Signaling

(2014) Yujun Gan et al.   MOLECULAR ENDOCRINOLOGY

Silencing of insulin-like growth factor-1 receptor enhances the radiation sensitivity of human esophageal squamous cell carcinoma in vitro and in vivo

(2014) Hui Zhao et al.   World Journal of Surgical Oncology

How IGF-1 activates its receptor

(2014) Jennifer M Kavran et al.   eLife

Insulin receptor compensates for IGF1R inhibition and directly induces mitogenic activity in prostate cancer cells

(2014) Doron Weinstein et al.   Endocrine Connections

Selection of Bone Metastasis Seeds by Mesenchymal Signals in the Primary Tumor Stroma

(2013) Xiang H.-F. Zhang et al.   CELL

An Integrin Binding-defective Mutant of Insulin-like Growth Factor-1 (R36E/R37E IGF1) Acts as a Dominant-negative Antagonist of the IGF1 Receptor (IGF1R) and Suppresses Tumorigenesis but Still Binds to IGF1R

(2013) Masaaki Fujita et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)

(2013) A. Pavlicek et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of Insulin-like Growth Factor-Binding Protein-3 Signaling through Sphingosine Kinase-1 Sensitizes Triple-Negative Breast Cancer Cells to EGF Receptor Blockade

(2013) J. L. Martin et al.   MOLECULAR CANCER THERAPEUTICS

Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin

(2013) K. Friedbichler et al.   MOLECULAR CANCER THERAPEUTICS

MM-141, an IGF-IR- and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

(2013) J. B. Fitzgerald et al.   MOLECULAR CANCER THERAPEUTICS

RNA interference in the nucleus: roles for small RNAs in transcription, epigenetics and beyond

(2013) Stephane E. Castel et al.   NATURE REVIEWS GENETICS

Anticarcinogenic effect of quercetin by inhibition of insulin-like growth factor (IGF)-1 signaling in mouse skin cancer

(2013) Minjeong Jung et al.   Nutrition Research and Practice

IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination

(2013) M M Chitnis et al.   ONCOGENE

Natural Products: Promising Resources for Cancer Drug Discovery

(2012) Susmita Mondal et al.   Anti-Cancer Agents in Medicinal Chemistry

Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathy

(2012) Terry J. Smith et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Evaluating Graves’ Orbitopathy

(2012) Peter J. Dolman   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

The Association Between IGF-I and Insulin Resistance: A general population study in Danish adults

(2012) N. Friedrich et al.   DIABETES CARE

Insulin-Like Growth Factor 2 in Development and Disease: A Mini-Review

(2012) Daniel Bergman et al.   GERONTOLOGY

The decline and fall of the IGF-I receptor

(2012) Renato Baserga   JOURNAL OF CELLULAR PHYSIOLOGY

The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents

(2012) M Z Lin et al.   ONCOGENE

Depletion of the type 1 IGF receptor delays repair of radiation-induced DNA double strand breaks

(2012) Benjamin W. Turney et al.   RADIOTHERAPY AND ONCOLOGY

Key questions and answers about pregnancy-associated plasma protein-A

(2012) Cheryl A. Conover   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Antibody-based therapeutics against components of the IGF system

(2012) Yang Feng et al.   OncoImmunology

Insulin-Like Growth Factor Binding Proteins: A Structural Perspective

(2012) Briony E. Forbes et al.   Frontiers in Endocrinology

Receptor Tyrosine Kinases and Targeted Cancer Therapeutics

(2011) Kenji Takeuchi et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Reply: ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’

(2011) A Gualberto et al.   BRITISH JOURNAL OF CANCER

Dual IGF-I/II-Neutralizing Antibody MEDI-573 Potently Inhibits IGF Signaling and Tumor Growth

(2011) J. Gao et al.   CANCER RESEARCH

A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors

(2011) F. Atzori et al.   CLINICAL CANCER RESEARCH

Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells

(2011) Zohar Attias-Geva et al.   EUROPEAN JOURNAL OF CANCER

Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies

(2011) Rachel Steuerman et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Insulin-like Growth Factor-I Receptor (IGF-IR) Translocates to Nucleus and AutoregulatesIGF-IRGene Expression in Breast Cancer Cells

(2011) Rive Sarfstein et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study

(2011) Alberto S. Pappo et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Erlotinib in Combination With Placebo or R1507, a Monoclonal Antibody to Insulin-Like Growth Factor-1 Receptor, for Advanced-Stage Non–Small-Cell Lung Cancer

(2011) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group

(2011) Suman Malempati et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinically useful anticancer, antitumor, and antiwrinkle agent, ursolic acid and related derivatives as medicinally important natural product

(2011) Nighat Sultana   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Efficacy of Ganitumab (AMG 479), Alone and in Combination with Rapamycin, in Ewing's and Osteogenic Sarcoma Models

(2011) P. J. Beltran et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2

(2011) H. K. Bid et al.   MOLECULAR CANCER THERAPEUTICS

Over-stimulation of insulin/IGF-1 signaling by western diet may promote diseases of civilization: lessons learnt from laron syndrome

(2011) Bodo C Melnik et al.   Nutrition & Metabolism

Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer

(2011) H Werner   ONCOGENE

A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer

(2011) Terence Friedlander   ONCOLOGY REPORTS

Growth Hormone Receptor Deficiency Is Associated with a Major Reduction in Pro-Aging Signaling, Cancer, and Diabetes in Humans

(2011) J. Guevara-Aguirre et al.   Science Translational Medicine

PAPP-A: a new anti-aging target?

(2010) Cheryl A. Conover   AGING CELL

A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer

(2010) Charles J. Ryan et al.   BJU INTERNATIONAL

Type 1 Insulin-like Growth Factor Receptor Translocates to the Nucleus of Human Tumor Cells

(2010) T. Aleksic et al.   CANCER RESEARCH

A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors

(2010) R. Kurzrock et al.   CLINICAL CANCER RESEARCH

Nutrition and acne

(2010) F. William Danby   CLINICS IN DERMATOLOGY

Prediction of incident diabetes mellitus by baseline IGF1 levels

(2010) Harald Jörn Schneider et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Effect of insulin-like growth factor-1 deficiency or administration on the occurrence of acne

(2010) D. Ben-Amitai et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Longevity and Age-Related Pathology of Mice Deficient in Pregnancy-Associated Plasma Protein-A

(2010) Cheryl A. Conover et al.   JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES

Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies

(2010)   LANCET ONCOLOGY

Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer

(2010) E. Buck et al.   MOLECULAR CANCER THERAPEUTICS

Insulin-Like Growth Factor-I Regulation of Immune Function: A Potential Therapeutic Target in Autoimmune Diseases?

(2010) T. J. Smith   PHARMACOLOGICAL REVIEWS

Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy

(2010) D. B. Ulanet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

SUMOylation Mediates the Nuclear Translocation and Signaling of the IGF-1 Receptor

(2010) B. Sehat et al.   Science Signaling

Sequencing of Type I Insulin-Like Growth Factor Receptor Inhibition Affects Chemotherapy Response In vitro and In vivo

(2009) X. Zeng et al.   CLINICAL CANCER RESEARCH

Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy

(2009) J. Veeken et al.   CURRENT CANCER DRUG TARGETS

Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and Disease

(2009) Antonino Belfiore et al.   ENDOCRINE REVIEWS

Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor

(2009) Mark J Mulvihill et al.   Future Medicinal Chemistry

Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1

(2009) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach

(2009) Rongshi Li et al.   JOURNAL OF MEDICINAL CHEMISTRY

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

(2009) David Olmos et al.   LANCET ONCOLOGY

Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer

(2009) J. S.P. Yuen et al.   MOLECULAR CANCER THERAPEUTICS

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR

(2009) J. M. Carboni et al.   MOLECULAR CANCER THERAPEUTICS

Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer

(2009) Junya Furukawa et al.   PROSTATE

The Type 1 Insulin-Like Growth Factor Receptor Pathway

(2008) M. M. Chitnis et al.   CLINICAL CANCER RESEARCH

Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma

(2008) Martha Q. Lacy et al.   JOURNAL OF CLINICAL ONCOLOGY

IGF-1 Receptor Inhibitors in Clinical Trials—Early Lessons

(2008) S. John Weroha et al.   JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA

Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors

(2008) C. Tarn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma

(2008) Kai Breuhahn   WORLD JOURNAL OF GASTROENTEROLOGY

IGF-1 Induces SREBP-1 Expression and Lipogenesis in SEB-1 Sebocytes via Activation of the Phosphoinositide 3-Kinase/Akt Pathway

(2007) Terry M. Smith et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY